U.S. markets open in 4 hours 2 minutes

Pluristem Therapeutics Inc. (PSTI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.7300+0.0800 (+3.02%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.6500
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range2.6300 - 2.8300
52 Week Range2.4400 - 11.8500
Avg. Volume194,243
Market Cap87.373M
Beta (5Y Monthly)2.30
PE Ratio (TTM)N/A
EPS (TTM)-1.7740
Earnings DateFeb 16, 2019 - Feb 19, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.92
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PSTI

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pluristem Therapeutics, Inc.
    VCEL: Lowering target price to $52.00VERICEL CORP has an Investment Rating of HOLD; a target price of $52.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • GlobeNewswire

    Pluristem CEO Issues Shareholder Update

    Figure 1 Clinical Pipeline: Milestones HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. Dear Shareholders, Less than three months into a new fiscal year, there are several important developments on the horizon for Pluristem, including four studies heading to clinical readout in the coming quarters. These s

  • Simply Wall St.

    Will Pluristem Therapeutics (NASDAQ:PSTI) Spend Its Cash Wisely?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Insider Monkey

    Cathie Wood is Getting Rid of These 10 Stocks

    In this article, we discuss the 10 stocks Cathie Wood is getting rid of. If you want to skip our detailed analysis of these stocks, go directly to Cathie Wood is Getting Rid of These 5 Stocks. Cathie Wood, the chief of New York-based ARK Investment Management, has become famous on Wall Street in recent […]